PMC:7205724 / 18009-18542 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"633","span":{"begin":59,"end":68},"obj":"Species"},{"id":"634","span":{"begin":293,"end":301},"obj":"Species"},{"id":"635","span":{"begin":5,"end":13},"obj":"Species"},{"id":"636","span":{"begin":98,"end":107},"obj":"Disease"},{"id":"637","span":{"begin":307,"end":314},"obj":"Disease"},{"id":"638","span":{"begin":433,"end":440},"obj":"Disease"},{"id":"639","span":{"begin":524,"end":532},"obj":"Disease"}],"attributes":[{"id":"A633","pred":"tao:has_database_id","subj":"633","obj":"Tax:2697049"},{"id":"A634","pred":"tao:has_database_id","subj":"634","obj":"Tax:9606"},{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"Tax:9606"},{"id":"A636","pred":"tao:has_database_id","subj":"636","obj":"MESH:D007239"},{"id":"A637","pred":"tao:has_database_id","subj":"637","obj":"MESH:C000657245"},{"id":"A638","pred":"tao:has_database_id","subj":"638","obj":"MESH:C000657245"},{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T137","span":{"begin":132,"end":137},"obj":"Body_part"},{"id":"T138","span":{"begin":214,"end":217},"obj":"Body_part"},{"id":"T139","span":{"begin":222,"end":225},"obj":"Body_part"},{"id":"T140","span":{"begin":357,"end":371},"obj":"Body_part"}],"attributes":[{"id":"A137","pred":"fma_id","subj":"T137","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A138","pred":"fma_id","subj":"T138","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A139","pred":"fma_id","subj":"T139","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A140","pred":"fma_id","subj":"T140","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T20","span":{"begin":132,"end":137},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T133","span":{"begin":98,"end":107},"obj":"Disease"},{"id":"T134","span":{"begin":307,"end":314},"obj":"Disease"},{"id":"T135","span":{"begin":433,"end":440},"obj":"Disease"},{"id":"T136","span":{"begin":524,"end":532},"obj":"Disease"}],"attributes":[{"id":"A133","pred":"mondo_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A134","pred":"mondo_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A135","pred":"mondo_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A136","pred":"mondo_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T224","span":{"begin":45,"end":47},"obj":"http://purl.obolibrary.org/obo/CLO_0008192"},{"id":"T225","span":{"begin":115,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T226","span":{"begin":245,"end":247},"obj":"http://purl.obolibrary.org/obo/CLO_0008192"},{"id":"T227","span":{"begin":251,"end":253},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T228","span":{"begin":283,"end":285},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T156","span":{"begin":45,"end":47},"obj":"Chemical"},{"id":"T159","span":{"begin":245,"end":247},"obj":"Chemical"}],"attributes":[{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A157","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_53793"},{"id":"A158","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_73425"},{"id":"A159","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A160","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_53793"},{"id":"A161","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_73425"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-MedDRA

    {"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T13","span":{"begin":357,"end":371},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A13","pred":"meddra_id","subj":"T13","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-PD-IDO

    {"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T78","span":{"begin":98,"end":107},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T79","span":{"begin":178,"end":185},"obj":"http://purl.obolibrary.org/obo/OGMS_0000020"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-PD-NCBITaxon

    {"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T179","span":{"begin":59,"end":68},"obj":"Species"},{"id":"T180","span":{"begin":307,"end":314},"obj":"Species"},{"id":"T181","span":{"begin":433,"end":440},"obj":"Species"},{"id":"T182","span":{"begin":524,"end":532},"obj":"Species"}],"attributes":[{"id":"A179","pred":"ncbi_taxonomy_id","subj":"T179","obj":"NCBItxid:2697049"},{"id":"A180","pred":"ncbi_taxonomy_id","subj":"T180","obj":"NCBItxid:2697049"},{"id":"A181","pred":"ncbi_taxonomy_id","subj":"T181","obj":"NCBItxid:2697049"},{"id":"A182","pred":"ncbi_taxonomy_id","subj":"T182","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-sentences

    {"project":"LitCovid-sample-sentences","denotations":[{"id":"T145","span":{"begin":0,"end":119},"obj":"Sentence"},{"id":"T146","span":{"begin":120,"end":315},"obj":"Sentence"},{"id":"T147","span":{"begin":316,"end":441},"obj":"Sentence"},{"id":"T148","span":{"begin":442,"end":533},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-PD-UBERON

    {"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T20","span":{"begin":132,"end":137},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-Pubtator

    {"project":"LitCovid-sample-Pubtator","denotations":[{"id":"635","span":{"begin":5,"end":13},"obj":"Species"},{"id":"633","span":{"begin":59,"end":68},"obj":"Species"},{"id":"636","span":{"begin":98,"end":107},"obj":"Disease"},{"id":"634","span":{"begin":293,"end":301},"obj":"Species"},{"id":"637","span":{"begin":307,"end":314},"obj":"Disease"},{"id":"638","span":{"begin":433,"end":440},"obj":"Disease"},{"id":"639","span":{"begin":524,"end":532},"obj":"Disease"}],"attributes":[{"id":"A639","pred":"pubann:denotes","subj":"639","obj":"MESH:C000657245"},{"id":"A634","pred":"pubann:denotes","subj":"634","obj":"Tax:9606"},{"id":"A636","pred":"pubann:denotes","subj":"636","obj":"MESH:D007239"},{"id":"A633","pred":"pubann:denotes","subj":"633","obj":"Tax:2697049"},{"id":"A638","pred":"pubann:denotes","subj":"638","obj":"MESH:C000657245"},{"id":"A635","pred":"pubann:denotes","subj":"635","obj":"Tax:9606"},{"id":"A637","pred":"pubann:denotes","subj":"637","obj":"MESH:C000657245"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-UniProt

    {"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1971","span":{"begin":52,"end":55},"obj":"Protein"},{"id":"T1980","span":{"begin":267,"end":270},"obj":"Protein"}],"attributes":[{"id":"A1971","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/Q63492"},{"id":"A1972","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/Q63491"},{"id":"A1973","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/Q62815"},{"id":"A1974","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/Q62691"},{"id":"A1975","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/Q01542"},{"id":"A1976","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/P27732"},{"id":"A1977","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/O09024"},{"id":"A1978","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/O09023"},{"id":"A1979","pred":"uniprot_id","subj":"T1971","obj":"https://www.uniprot.org/uniprot/O09022"},{"id":"A1980","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/Q63492"},{"id":"A1981","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/Q63491"},{"id":"A1982","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/Q62815"},{"id":"A1983","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/Q62691"},{"id":"A1984","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/Q01542"},{"id":"A1985","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/P27732"},{"id":"A1986","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/O09024"},{"id":"A1987","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/O09023"},{"id":"A1988","pred":"uniprot_id","subj":"T1980","obj":"https://www.uniprot.org/uniprot/O09022"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-Enju

    {"project":"LitCovid-sample-Enju","denotations":[{"id":"T8813","span":{"begin":0,"end":4},"obj":"JJS"},{"id":"T48684","span":{"begin":5,"end":13},"obj":"NNS"},{"id":"T37814","span":{"begin":14,"end":21},"obj":"VBP"},{"id":"T41895","span":{"begin":22,"end":32},"obj":"NNS"},{"id":"T32237","span":{"begin":33,"end":40},"obj":"IN"},{"id":"T55833","span":{"begin":41,"end":44},"obj":"DT"},{"id":"T23466","span":{"begin":45,"end":47},"obj":"NN"},{"id":"T51386","span":{"begin":48,"end":51},"obj":"CC"},{"id":"T97267","span":{"begin":52,"end":55},"obj":"NN"},{"id":"T48238","span":{"begin":56,"end":58},"obj":"IN"},{"id":"T17626","span":{"begin":59,"end":68},"obj":"NN"},{"id":"T87676","span":{"begin":69,"end":75},"obj":"IN"},{"id":"T56543","span":{"begin":76,"end":79},"obj":"DT"},{"id":"T74019","span":{"begin":80,"end":86},"obj":"JJ"},{"id":"T36179","span":{"begin":87,"end":91},"obj":"NN"},{"id":"T61939","span":{"begin":92,"end":97},"obj":"IN"},{"id":"T53819","span":{"begin":98,"end":107},"obj":"NN"},{"id":"T47949","span":{"begin":108,"end":113},"obj":"NN"},{"id":"T10621","span":{"begin":114,"end":115},"obj":"-LRB-"},{"id":"T31327","span":{"begin":115,"end":117},"obj":"CD"},{"id":"T53799","span":{"begin":117,"end":118},"obj":"-RRB-"},{"id":"T76985","span":{"begin":120,"end":128},"obj":"NN"},{"id":"T6758","span":{"begin":129,"end":131},"obj":"IN"},{"id":"T88720","span":{"begin":132,"end":137},"obj":"NN"},{"id":"T73739","span":{"begin":138,"end":145},"obj":"NNS"},{"id":"T20072","span":{"begin":146,"end":155},"obj":"VBD"},{"id":"T30704","span":{"begin":156,"end":158},"obj":"CD"},{"id":"T66398","span":{"begin":159,"end":161},"obj":"CC"},{"id":"T43796","span":{"begin":162,"end":166},"obj":"JJR"},{"id":"T64515","span":{"begin":167,"end":171},"obj":"NNS"},{"id":"T88119","span":{"begin":172,"end":177},"obj":"IN"},{"id":"T33297","span":{"begin":178,"end":185},"obj":"NN"},{"id":"T78997","span":{"begin":186,"end":191},"obj":"NN"},{"id":"T69102","span":{"begin":192,"end":200},"obj":"VBD"},{"id":"T51393","span":{"begin":201,"end":210},"obj":"NN"},{"id":"T49412","span":{"begin":211,"end":213},"obj":"IN"},{"id":"T86080","span":{"begin":214,"end":217},"obj":"NN"},{"id":"T42365","span":{"begin":218,"end":221},"obj":"CC"},{"id":"T24248","span":{"begin":222,"end":225},"obj":"NN"},{"id":"T84785","span":{"begin":226,"end":236},"obj":"NNS"},{"id":"T33598","span":{"begin":237,"end":244},"obj":"IN"},{"id":"T65176","span":{"begin":245,"end":247},"obj":"NN"},{"id":"T29543","span":{"begin":248,"end":250},"obj":"IN"},{"id":"T67075","span":{"begin":251,"end":253},"obj":"CD"},{"id":"T4274","span":{"begin":253,"end":254},"obj":"NN"},{"id":"T73088","span":{"begin":255,"end":258},"obj":"CC"},{"id":"T74097","span":{"begin":259,"end":261},"obj":"CD"},{"id":"T71868","span":{"begin":261,"end":262},"obj":"NN"},{"id":"T54079","span":{"begin":263,"end":266},"obj":"CC"},{"id":"T73098","span":{"begin":267,"end":270},"obj":"NN"},{"id":"T69539","span":{"begin":271,"end":273},"obj":"IN"},{"id":"T87988","span":{"begin":274,"end":277},"obj":"CD"},{"id":"T78691","span":{"begin":277,"end":278},"obj":"NN"},{"id":"T18580","span":{"begin":279,"end":282},"obj":"CC"},{"id":"T46489","span":{"begin":283,"end":285},"obj":"CD"},{"id":"T64615","span":{"begin":285,"end":286},"obj":"NN"},{"id":"T60810","span":{"begin":287,"end":292},"obj":"IN"},{"id":"T38563","span":{"begin":293,"end":301},"obj":"NNS"},{"id":"T93829","span":{"begin":302,"end":306},"obj":"IN"},{"id":"T24980","span":{"begin":307,"end":314},"obj":"NN"},{"id":"T89545","span":{"begin":316,"end":323},"obj":"NNS"},{"id":"T44838","span":{"begin":324,"end":336},"obj":"RB"},{"id":"T54246","span":{"begin":337,"end":341},"obj":"VBP"},{"id":"T20581","span":{"begin":342,"end":346},"obj":"IN"},{"id":"T54967","span":{"begin":347,"end":356},"obj":"VBN"},{"id":"T27422","span":{"begin":357,"end":371},"obj":"NN"},{"id":"T48431","span":{"begin":372,"end":378},"obj":"NNS"},{"id":"T7060","span":{"begin":379,"end":388},"obj":"VBP"},{"id":"T92743","span":{"begin":389,"end":392},"obj":"DT"},{"id":"T24866","span":{"begin":393,"end":403},"obj":"NN"},{"id":"T9522","span":{"begin":404,"end":408},"obj":"IN"},{"id":"T69120","span":{"begin":409,"end":414},"obj":"JJ"},{"id":"T81312","span":{"begin":415,"end":417},"obj":"TO"},{"id":"T7048","span":{"begin":418,"end":422},"obj":"JJ"},{"id":"T25388","span":{"begin":423,"end":429},"obj":"NN"},{"id":"T44741","span":{"begin":430,"end":432},"obj":"IN"},{"id":"T20679","span":{"begin":433,"end":440},"obj":"NN"},{"id":"T6735","span":{"begin":442,"end":444},"obj":"PRP"},{"id":"T32751","span":{"begin":445,"end":450},"obj":"VBZ"},{"id":"T41840","span":{"begin":451,"end":454},"obj":"DT"},{"id":"T21434","span":{"begin":455,"end":466},"obj":"NN"},{"id":"T75450","span":{"begin":467,"end":471},"obj":"IN"},{"id":"T55251","span":{"begin":472,"end":476},"obj":"NN"},{"id":"T48129","span":{"begin":477,"end":484},"obj":"NN"},{"id":"T90120","span":{"begin":485,"end":490},"obj":"MD"},{"id":"T91321","span":{"begin":491,"end":495},"obj":"VB"},{"id":"T89890","span":{"begin":496,"end":498},"obj":"TO"},{"id":"T64443","span":{"begin":499,"end":509},"obj":"VB"},{"id":"T5150","span":{"begin":510,"end":518},"obj":"NN"},{"id":"T43666","span":{"begin":519,"end":523},"obj":"IN"},{"id":"T85289","span":{"begin":524,"end":532},"obj":"NN"}],"relations":[{"id":"R18045","pred":"arg1Of","subj":"T48684","obj":"T8813"},{"id":"R91845","pred":"arg1Of","subj":"T48684","obj":"T37814"},{"id":"R13100","pred":"arg2Of","subj":"T41895","obj":"T37814"},{"id":"R35710","pred":"arg1Of","subj":"T37814","obj":"T32237"},{"id":"R20807","pred":"arg2Of","subj":"T51386","obj":"T32237"},{"id":"R6800","pred":"arg1Of","subj":"T51386","obj":"T55833"},{"id":"R22109","pred":"arg1Of","subj":"T23466","obj":"T51386"},{"id":"R81797","pred":"arg2Of","subj":"T97267","obj":"T51386"},{"id":"R91140","pred":"arg1Of","subj":"T51386","obj":"T48238"},{"id":"R87740","pred":"arg2Of","subj":"T17626","obj":"T48238"},{"id":"R8876","pred":"arg1Of","subj":"T37814","obj":"T87676"},{"id":"R35461","pred":"arg2Of","subj":"T36179","obj":"T87676"},{"id":"R97441","pred":"arg1Of","subj":"T36179","obj":"T56543"},{"id":"R2585","pred":"arg1Of","subj":"T36179","obj":"T74019"},{"id":"R34363","pred":"arg1Of","subj":"T37814","obj":"T61939"},{"id":"R46687","pred":"arg2Of","subj":"T47949","obj":"T61939"},{"id":"R33556","pred":"arg1Of","subj":"T47949","obj":"T53819"},{"id":"R6993","pred":"arg1Of","subj":"T37814","obj":"T10621"},{"id":"R3294","pred":"arg2Of","subj":"T31327","obj":"T10621"},{"id":"R78306","pred":"arg3Of","subj":"T53799","obj":"T10621"},{"id":"R98284","pred":"arg1Of","subj":"T76985","obj":"T6758"},{"id":"R72949","pred":"arg2Of","subj":"T73739","obj":"T6758"},{"id":"R94093","pred":"arg1Of","subj":"T73739","obj":"T88720"},{"id":"R64474","pred":"arg1Of","subj":"T76985","obj":"T20072"},{"id":"R79737","pred":"arg2Of","subj":"T64515","obj":"T20072"},{"id":"R31087","pred":"arg1Of","subj":"T64515","obj":"T30704"},{"id":"R58487","pred":"arg1Of","subj":"T30704","obj":"T66398"},{"id":"R48701","pred":"arg1Of","subj":"T30704","obj":"T43796"},{"id":"R91116","pred":"arg1Of","subj":"T20072","obj":"T88119"},{"id":"R29180","pred":"arg2Of","subj":"T69102","obj":"T88119"},{"id":"R61094","pred":"arg1Of","subj":"T78997","obj":"T33297"},{"id":"R30751","pred":"arg1Of","subj":"T78997","obj":"T69102"},{"id":"R85646","pred":"arg2Of","subj":"T51393","obj":"T69102"},{"id":"R94930","pred":"arg1Of","subj":"T51393","obj":"T49412"},{"id":"R15007","pred":"arg2Of","subj":"T84785","obj":"T49412"},{"id":"R35220","pred":"arg1Of","subj":"T84785","obj":"T86080"},{"id":"R17029","pred":"arg1Of","subj":"T86080","obj":"T42365"},{"id":"R36223","pred":"arg2Of","subj":"T24248","obj":"T42365"},{"id":"R4871","pred":"arg1Of","subj":"T84785","obj":"T24248"},{"id":"R37373","pred":"arg1Of","subj":"T51393","obj":"T33598"},{"id":"R80609","pred":"arg2Of","subj":"T65176","obj":"T33598"},{"id":"R29116","pred":"arg1Of","subj":"T51393","obj":"T29543"},{"id":"R74727","pred":"arg2Of","subj":"T54079","obj":"T29543"},{"id":"R31620","pred":"arg1Of","subj":"T4274","obj":"T67075"},{"id":"R41074","pred":"arg1Of","subj":"T71868","obj":"T4274"},{"id":"R32415","pred":"arg1Of","subj":"T4274","obj":"T73088"},{"id":"R53047","pred":"arg2Of","subj":"T74097","obj":"T73088"},{"id":"R60224","pred":"arg1Of","subj":"T71868","obj":"T74097"},{"id":"R30825","pred":"arg1Of","subj":"T71868","obj":"T54079"},{"id":"R92508","pred":"arg2Of","subj":"T73098","obj":"T54079"},{"id":"R99739","pred":"arg1Of","subj":"T54079","obj":"T69539"},{"id":"R9744","pred":"arg2Of","subj":"T64615","obj":"T69539"},{"id":"R73124","pred":"arg1Of","subj":"T78691","obj":"T87988"},{"id":"R67370","pred":"arg1Of","subj":"T64615","obj":"T78691"},{"id":"R15728","pred":"arg1Of","subj":"T78691","obj":"T18580"},{"id":"R74845","pred":"arg2Of","subj":"T46489","obj":"T18580"},{"id":"R42305","pred":"arg1Of","subj":"T64615","obj":"T46489"},{"id":"R38001","pred":"arg1Of","subj":"T51393","obj":"T60810"},{"id":"R89986","pred":"arg2Of","subj":"T38563","obj":"T60810"},{"id":"R54593","pred":"arg1Of","subj":"T38563","obj":"T93829"},{"id":"R6445","pred":"arg2Of","subj":"T24980","obj":"T93829"},{"id":"R86911","pred":"arg1Of","subj":"T54246","obj":"T44838"},{"id":"R41127","pred":"arg1Of","subj":"T89545","obj":"T54246"},{"id":"R52555","pred":"arg2Of","subj":"T7060","obj":"T54246"},{"id":"R1890","pred":"arg1Of","subj":"T7060","obj":"T20581"},{"id":"R15150","pred":"arg2Of","subj":"T48431","obj":"T54967"},{"id":"R79272","pred":"arg1Of","subj":"T48431","obj":"T27422"},{"id":"R9994","pred":"arg1Of","subj":"T48431","obj":"T7060"},{"id":"R27595","pred":"arg2Of","subj":"T24866","obj":"T7060"},{"id":"R10059","pred":"arg1Of","subj":"T24866","obj":"T92743"},{"id":"R64970","pred":"arg1Of","subj":"T24866","obj":"T9522"},{"id":"R11593","pred":"arg2Of","subj":"T25388","obj":"T9522"},{"id":"R11280","pred":"arg1Of","subj":"T7048","obj":"T69120"},{"id":"R61089","pred":"arg1Of","subj":"T7048","obj":"T81312"},{"id":"R36970","pred":"arg1Of","subj":"T25388","obj":"T7048"},{"id":"R76248","pred":"arg1Of","subj":"T25388","obj":"T44741"},{"id":"R16578","pred":"arg2Of","subj":"T20679","obj":"T44741"},{"id":"R93295","pred":"arg1Of","subj":"T6735","obj":"T32751"},{"id":"R68469","pred":"arg2Of","subj":"T21434","obj":"T32751"},{"id":"R17888","pred":"arg1Of","subj":"T21434","obj":"T41840"},{"id":"R71902","pred":"arg2Of","subj":"T91321","obj":"T21434"},{"id":"R4510","pred":"arg1Of","subj":"T91321","obj":"T75450"},{"id":"R34056","pred":"arg1Of","subj":"T48129","obj":"T55251"},{"id":"R30440","pred":"arg1Of","subj":"T48129","obj":"T90120"},{"id":"R46659","pred":"arg2Of","subj":"T91321","obj":"T90120"},{"id":"R94505","pred":"arg1Of","subj":"T48129","obj":"T91321"},{"id":"R59227","pred":"arg2Of","subj":"T64443","obj":"T91321"},{"id":"R39248","pred":"arg1Of","subj":"T64443","obj":"T89890"},{"id":"R27615","pred":"arg1Of","subj":"T48129","obj":"T64443"},{"id":"R41612","pred":"arg2Of","subj":"T5150","obj":"T64443"},{"id":"R13579","pred":"arg1Of","subj":"T5150","obj":"T43666"},{"id":"R80924","pred":"arg2Of","subj":"T85289","obj":"T43666"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-PD-FMA

    {"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T137","span":{"begin":132,"end":137},"obj":"Body_part"},{"id":"T138","span":{"begin":214,"end":217},"obj":"Body_part"},{"id":"T139","span":{"begin":222,"end":225},"obj":"Body_part"},{"id":"T140","span":{"begin":357,"end":371},"obj":"Body_part"}],"attributes":[{"id":"A137","pred":"fma_id","subj":"T137","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A138","pred":"fma_id","subj":"T138","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A139","pred":"fma_id","subj":"T139","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A140","pred":"fma_id","subj":"T140","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-PD-MONDO

    {"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T128","span":{"begin":98,"end":107},"obj":"Disease"},{"id":"T129","span":{"begin":307,"end":314},"obj":"Disease"},{"id":"T130","span":{"begin":433,"end":440},"obj":"Disease"},{"id":"T131","span":{"begin":524,"end":532},"obj":"Disease"}],"attributes":[{"id":"A131","pred":"mondo_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A130","pred":"mondo_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A129","pred":"mondo_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A128","pred":"mondo_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sample-PD-HP

    {"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T8","span":{"begin":347,"end":378},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0010702"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T145","span":{"begin":0,"end":119},"obj":"Sentence"},{"id":"T146","span":{"begin":120,"end":315},"obj":"Sentence"},{"id":"T147","span":{"begin":316,"end":441},"obj":"Sentence"},{"id":"T148","span":{"begin":442,"end":533},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":347,"end":378},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0010702"}],"text":"Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19."}